☆ 4.5 Article

Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma

NATURE CANCER (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis

Wen Wen et al.

Summary: This study conducted a meta-analysis on three new oral antivirals (molnupiravir, fluvoxamine, and Paxlovid) and their effects on mortality and hospitalization rates among COVID-19 patients. The results showed that these drugs were effective in reducing mortality and hospitalization rates by approximately 67%. Furthermore, the drugs did not increase adverse events, indicating good overall safety.

ANNALS OF MEDICINE (2022)

Add to Collection

Review Oncology

Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review

C. Corti et al.

Summary: This systematic review investigates the immunogenicity of COVID-19 vaccines in patients with cancer (PsC). The results show that vaccination against COVID-19 is generally safe and immunogenic for PsC. However, the seroconversion rate in PsC is lower, lagged, or both compared to the general population. Patients with hematologic malignancies, especially those receiving B-cell-depleting agents in the past 12 months, are at the highest risk of poor seroconversion.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Hematology

Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients

Nora Liebers et al.

BLOOD (2022)

Add to Collection

Article Hematology

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients

Alexis Maillard et al.

BLOOD (2022)

Add to Collection

Article Hematology

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia (CLL) have impaired antibody response to COVID-19 vaccination. A third dose of the vaccine can improve the antibody response in some CLL patients. Patients on active treatment and those recently treated with anti-CD20 therapy have lower antibody response rates.

BLOOD (2022)

Add to Collection

Article Hematology

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma

Julius C. Enssle et al.

BLOOD (2022)

Add to Collection

Letter Oncology

Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer

Lauren C. Shapiro et al.

CANCER CELL (2022)

Add to Collection

Article Oncology

Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer

Vivek Naranbhai et al.

Summary: Patients with cancer have impaired immune responses to SARS-CoV-2 vaccines, and the type and timing of vaccination affect the breadth of immune responses against variants. Concentrations of anti-spike protein antibodies serve as a good surrogate for breadth, and booster doses increase the breadth of immune responses against variants.

CANCER CELL (2022)

Add to Collection

Article Oncology

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study

Vivek Naranbhai et al.

Summary: The study investigated the immune responses to SARS-CoV-2 vaccines in cancer patients, showing that the vaccine-induced immune responses were quantitatively lower in cancer patients compared to healthy controls, recommending antibody testing to identify those who may benefit from additional vaccine doses.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Delphine Planas et al.

Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.

NATURE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern

Paul R. Wratil et al.

Summary: This study reports on the dynamics of neutralizing antibodies in individuals convalescing from coronavirus disease 2019 or who are vaccine-naive and subsequently vaccinated. The findings suggest that infection-plus-vaccination-induced hybrid immunity or triple immunization can induce high-quality antibodies with superior neutralization capacity against variants of concern, including omicron.

NATURE MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Henning Gruell et al.

Summary: This study demonstrates that neutralization of the SARS-CoV-2 Omicron variant is greatly reduced in individuals who received two doses of the COVID-19 vaccine or have recovered from the disease, but is significantly increased after a booster vaccine dose.

NATURE MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

Plasma Neutralization of the SARS-CoV-2 Omicron Variant

Fabian Schmidt et al.

Summary: Neutralization assays showed much lower omicron neutralization compared to Wuhan-hu-1 after two doses of mRNA vaccine, but individuals who received a booster vaccine or were vaccinated after recovering from Covid-19 exhibited high levels of omicron neutralization.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Peter B. Gilbert et al.

Summary: In the COVE phase 3 clinical trial, neutralizing and binding antibodies were measured in vaccine recipients to determine their correlation with COVID-19 risk and vaccine efficacy. The results showed that these immune markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Postvaccination neutralization titers of 10, 100, and 1000 correlated with estimated vaccine efficacies of 78%, 91%, and 96% respectively.

SCIENCE (2022)

Add to Collection

Review Oncology

COVID-19 vaccination in patients with cancer, a rapid review

Laudy Chehade et al.

Summary: This review examines the efficacy of COVID-19 vaccines in cancer patients and finds that solid tumor patients have lower serologic response rates compared to healthy controls, while patients with hematologic malignancies have the lowest response rates. Patients receiving B-cell depleting therapies have poor serologic responses. Data on cellular response are limited and conflicting. Many questions about vaccination in cancer patients remain unanswered and require further exploration.

ECANCERMEDICALSCIENCE (2022)

Add to Collection

Correction Oncology

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer (vol 40, pg 114, 2022)

Annika Fendler et al.

CANCER CELL (2022)

Add to Collection

Letter Oncology

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

Robert Stuver et al.

CANCER CELL (2022)

Add to Collection

Letter Oncology

COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia

Helen Parry et al.

CANCER CELL (2022)

Add to Collection

Letter Oncology

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

Adolfo Aleman et al.

CANCER CELL (2022)

Add to Collection

Letter Oncology

Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma

Julius C. Enssle et al.

CANCER CELL (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Humoral and cellular immune memory to four COVID-19 vaccines

Zeli Zhang et al.

Summary: Multiple COVID-19 vaccines have successfully protected against symptomatic cases and deaths. Comparisons of T cell, B cell, and antibody responses to different vaccines can provide insights into protective immunity against COVID-19, particularly immune memory. mRNA vaccines and Ad26.COV2.S induced strong T cell responses, while mRNA vaccines showed substantial declines in antibodies.

CELL (2022)

Add to Collection

Article Infectious Diseases

In-depth profiling of COVID-19 risk factors and preventive measures in healthcare workers

Paul R. Wratil et al.

Summary: This study aimed to determine risk factors for COVID-19 in healthcare workers, characterize symptoms, and evaluate preventive measures against SARS-CoV-2 spread in hospitals. The results showed that nurses, staff working on COVID-19 units, males, and HCWs reporting high-risk exposures to infected patients or outside of work had an increased risk of COVID-19.

INFECTION (2022)

Add to Collection

Article Medicine, General & Internal

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Anil Gupta et al.

Summary: The study showed that sotrovimab treatment significantly reduced the risk of all-cause hospitalization or death in nonhospitalized patients with mild to moderate COVID-19 and at risk of disease progression. Sotrovimab also decreased the risk of emergency department visits, hospitalization, or death, as well as the progression to severe or critical respiratory COVID-19. Adverse events were similar between the treatment and placebo groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Letter Urology & Nephrology

Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant

Ilies Benotmane et al.

KIDNEY INTERNATIONAL (2022)

Add to Collection

Review Oncology

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Annika Fendler et al.

Summary: The efficacy and immunogenicity of COVID-19 vaccines in cancer patients are uncertain due to their exclusion from pivotal clinical trials. In this Review, the current knowledge on vaccine efficacy and immune responses in cancer patients is summarized, highlighting key factors that may affect vaccine efficacy in this population.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Add to Collection

Article Virology

Avidity of IgG to SARS-CoV-2 RBD as a Prognostic Factor for the Severity of COVID-19 Reinfection

Victor Manuylov et al.

Summary: The avidity index (AI) of IgG to the RBD of SARS-CoV-2 was higher in patients with mild reinfection than primary infection, indicating a positive correlation with disease severity. Meanwhile, patients with low-avidity antibodies during reinfection were more likely to develop severe forms of COVID-19.

VIRUSES-BASEL (2022)

Add to Collection

Review Infectious Diseases

Monoclonal antibody therapies against SARS-CoV-2

Daniele Focosi et al.

Summary: This paper reviews the use of monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 in the ongoing COVID-19 pandemic and discusses their therapeutic effects, structural classification, immune escape, and limitations. It also explores the impact of the Omicron variant on treatment strategies and potential future developments for improved outcomes.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Immunology

Dynamics of Neutralizing Antibodies and Binding Antibodies to Domains of SARS-CoV-2 Spike Protein in COVID-19 Survivors

Supinya Phakaratsakul et al.

Summary: The study observed the longitudinal changes in antibody levels of COVID-19 recovered patients, showing differences in dynamics between neutralizing antibodies and binding antibodies. Some patients had consistently high levels of neutralizing antibodies, while their binding antibodies rapidly decreased. Additionally, the presence of binding antibodies to S2 suggested an immune response to other coronaviruses.

VIRAL IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study

Sean H. Lim et al.

Summary: Patients with hematological malignancies, especially those undergoing active anticancer treatment or on anti-CD20 therapy, show compromised immune responses to COVID-19 vaccination. However, booster vaccination can significantly improve antibody responses in indolent B-cell lymphoma patients, and antigen-specific T-cell responses are observed in the majority of patients after a third dose, regardless of their cancer treatment status.

NATURE CANCER (2022)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Infectious Diseases

Genomic epidemiology reveals multiple introductions of SARS-CoV-2 followed by community and nosocomial spread, Germany, February to May 2020

Maximilian Muenchhoff et al.

Summary: Genomic epidemiology was used to trace the spread of SARS-CoV-2 in the Munich Metropolitan Region, revealing multiple independent introductions and high rates of hospital-acquired infections among patients and healthcare workers in the early weeks. The study illustrated how transmission chains can be dissected at high resolution using virus sequences and spatio-temporal networks of human interactions, highlighting the role of superspreading events and regional hotspots in catalysing the early spread of the virus in Europe.

EUROSURVEILLANCE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Rishi R. Goel et al.

Summary: This study found that immune memory to SARS-CoV-2 and its variants remains robust for at least 6 months after mRNA vaccination, with antibodies declining but still detectable in most individuals. mRNA vaccines also induced functional memory B cells and antigen-specific T cells, with recall responses primarily increasing antibody levels in individuals with preexisting immunity.

SCIENCE (2021)

Add to Collection

Article Microbiology

A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants

Denise Haslwanter et al.

Summary: The study identified a panel of potent RBD and NTD nAbs against SARS-CoV-2, with the most potent RBD nAb targeting a residue at F490 and the most potent NTD nAb epitope including Y145, K150, and W152. Combining RBD and NTD nAbs did not enhance neutralization potential but limited the development of neutralization-escape mutants in vitro, suggesting a potential strategy to mitigate the emergence of VOC.

MBIO (2021)

Add to Collection

Article Oncology

Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma

Srikanth Talluri et al.

Summary: The study revealed a crucial role of APOBEC/AID in multiple myeloma, leading to genomic instability, with APOBEC3G being a prominent mutational signature at diagnosis and relapse, significantly contributing to DNA damage and mutational changes in MM cells. These findings highlight APOBEC3G as a novel gene impacting genomic evolution and underlying mechanisms in MM.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Microbiology

Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy

Yusri Taha et al.

Summary: Two cases of persistent SARS-CoV-2 infection were successfully cleared with the monoclonal antibody combination casirivimab and imdevimab (REGN-COV2), highlighting the potential benefit of REGN-COV2 therapy for antibody deficient individuals. Further clinical studies are warranted to assess the effectiveness of REGN-COV2 in this patient population, especially in the context of emerging variants of concern like Omicron.

ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2021)

Add to Collection

Article Cell Biology

Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses

Paul R. Wratil et al.

Summary: Studies suggest that pre-existing immune responses to seasonal coronaviruses may increase susceptibility to SARS-CoV-2 and predispose individuals to adverse COVID-19 outcomes. This finding has important implications for risk management and the development of universal coronavirus vaccines.

CELL REPORTS (2021)

Add to Collection

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

Add to Collection

Letter Hematology

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose

Evangelos Terpos et al.

BLOOD (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Review Oncology

AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression

Pablo Oppezzo et al.

Summary: This review article discusses the dual role of the enzyme activation-induced cytidine deaminase (AID) in adaptive immunity and B-cell malignancies, emphasizing its pathological effects as a causative factor in leukemia and lymphomas. It summarizes the expression and function of AID in normal B lymphocytes, evaluates potential causes for AID expression in leukemic cells, and discusses its role in lymphomagenesis based on recent genomic landscape analyses of leukemia and lymphomas. The review also touches upon the correlation between AID off-target mutations and tumor-gene drivers in these cancers, and how these mutations could impact disease progression.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

P. Grivas et al.

Summary: This study analyzed clinical factors and laboratory measurements of cancer patients with COVID-19, finding that factors such as age, sex, comorbidities, cancer type, and laboratory results were associated with COVID-19 severity. Patients diagnosed early in the pandemic had worse outcomes, and specific anticancer therapies may increase 30-day all-cause mortality. More research is needed to confirm these findings and caution may be needed in using certain anticancer treatments.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Alfredo Addeo et al.

Summary: Among cancer patients, most (94%) achieved seroconversion after receiving two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response.

CANCER CELL (2021)

Add to Collection

Article Oncology

Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar et al.

Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.

CANCER CELL (2021)

Add to Collection

Letter Oncology

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

Lee Greenberger et al.

CANCER CELL (2021)

Add to Collection

Letter Oncology

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Oliver Van Oekelen et al.

CANCER CELL (2021)

Add to Collection

Letter Oncology

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Sidse Ehmsen et al.

CANCER CELL (2021)

Add to Collection

Article Immunology

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations

Frauke Muecksch et al.

Summary: This study examined the development of antibodies following infection with the coronavirus, finding that evolved antibodies had increased affinity and neutralization potency, altered mutational pathways for viral resistance, and restricted neutralization escape options. These findings suggest that increasing antibody diversity through prolonged or repeated antigen exposure may improve protection against diversifying populations of the virus and other pandemic threat coronaviruses.

IMMUNITY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Erin M. Bange et al.

Summary: In patients with cancer and COVID-19, those with hematologic cancer show impaired immune responses compared to solid cancer patients. CD8 T cells play a crucial role in survival, even in the presence of limited humoral responses. The presence of SARS-CoV-2-specific T cell responses in hematologic cancer patients suggests a potential therapeutic target.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Mark G. Thompson et al.

Summary: The study demonstrated that COVID-19 mRNA vaccines were highly effective in preventing SARS-CoV-2 infection in real-world conditions, while also attenuating the viral RNA load, febrile symptoms, and illness duration among vaccinated individuals who had breakthrough infections.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

Donal T. Skelly et al.

Summary: Vaccination with two doses generates more robust immune responses against emerging SARS-CoV-2 variants, particularly B.1.1.7 and B.1.351, compared to natural infection. High magnitude T cell responses are produced after two vaccine doses, mainly targeting conserved epitopes between the original isolate and the variants.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

Florent Malard et al.

Summary: This study evaluated the safety and immunogenicity of the BNT162b2 vaccine in patients with hematological malignancies. It found that only around half of the patients may achieve effective immune protection against COVID-19 after receiving two doses of the vaccine. Factors such as being male, receiving B-cell targeting treatment, and having low CD19(+) B-cell levels were associated with a decreased probability of achieving a protective level of anti-S IgG after the second dose.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Oncology

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Annika Fendler et al.

Summary: Patients with cancer have higher morbidity and mortality when infected with COVID-19. The CAPTURE study found that while most patients had immune responses against the original SARS-CoV-2, neutralizing antibody titers against variants were significantly reduced, with some patients experiencing a decrease in antibody levels. However, neutralizing antibody titers remained stable for some patients.

NATURE CANCER (2021)

Add to Collection

Article Oncology

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

Annika Fendler et al.

Summary: A cohort study evaluated 585 cancer patients following vaccination with BNT162b2 or AZD1222 vaccines, finding lower antibody responses in patients with hematological malignancies compared to those with solid tumors. Patients with hematological malignancies also had reduced neutralizing antibody responses compared to individuals without cancer. The study highlights the importance of managing cancer patients during the ongoing COVID-19 pandemic.

NATURE CANCER (2021)

Add to Collection

Article Oncology

Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy

Astha Thakkar et al.

Summary: The study found differential rates of SARS-CoV-2 IgG seroconversion in cancer patients based on specific cancer types and therapy modalities. Patients with hematological malignancies, those receiving anti-CD-20 antibody therapy, and stem cell transplant patients had significantly lower seroconversion rates, while patients receiving immunotherapy, especially anti-PD-1/PD-L1 monoclonal antibodies, showed 100% seroconversion rates. These findings have implications for clinical monitoring and vaccination strategies to combat the COVID-19 pandemic.

NATURE CANCER (2021)

Add to Collection

Letter Oncology

Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma

Francesco Maura et al.

LEUKEMIA (2020)

Add to Collection

Article Multidisciplinary Sciences

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Jose Mateus et al.

SCIENCE (2020)

Add to Collection

Article Oncology

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Lennard Y. W. Lee et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2

Bezawit A. Woldemeskel et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Article Oncology

Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

Laurence Albiges et al.

NATURE CANCER (2020)

Add to Collection

Article Oncology

SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer

Massimo Rugge et al.

NATURE CANCER (2020)

Add to Collection

Review Oncology

The immuno-oncological challenge of COVID-19

Lisa Derosa et al.

NATURE CANCER (2020)

Add to Collection

Letter Oncology

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

F. Maura et al.

LEUKEMIA (2018)

Add to Collection

Article Microbiology

Cross-sectional analysis of CD8 T cell immunity to human herpesvirus 6B

Larissa K. Martin et al.

PLOS PATHOGENS (2018)

Add to Collection

Article Multidisciplinary Sciences

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

Brian A. Walker et al.

NATURE COMMUNICATIONS (2015)

Add to Collection

Article Biochemical Research Methods

Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate

G. Almanzar et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2013)

Add to Collection

Article Hematology

Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma

Srinivas Koduru et al.

BLOOD (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.